Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.
Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, Rossi G, Vanni I, Longo L, Tagliamento M, Zullo L, Dal Bello MG, Dellepiane C, Alama A, Rijavec E, Ludovini V, Barletta G, Passiglia F, Metro G, Baglivo S, Chiari R, Rivoltini L, Biello F, Baraibar I, Gil-Bazo I, Novello S, Grossi F, Coco S. Genova C, et al. Among authors: grossi f. Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8. Clin Exp Med. 2024. PMID: 39105937 Free PMC article.
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F. Dal Bello MG, et al. Among authors: grossi f. J Transl Med. 2019 Mar 8;17(1):74. doi: 10.1186/s12967-019-1828-0. J Transl Med. 2019. PMID: 30849967 Free PMC article.
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C, Tasso R, Rosa A, Rossi G, Reverberi D, Fontana V, Marconi S, Croce M, Dal Bello MG, Dellepiane C, Tagliamento M, Ciferri MC, Zullo L, Fedeli A, Alama A, Cortese K, Gentili C, Cella E, Anselmi G, Mora M, Barletta G, Rijavec E, Grossi F, Pronzato P, Coco S. Genova C, et al. Among authors: grossi f. Cells. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832. Cells. 2023. PMID: 36980174 Free PMC article.
Role of microRNAs in malignant mesothelioma.
Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, Grossi F. Truini A, et al. Among authors: grossi f. Cell Mol Life Sci. 2014 Aug;71(15):2865-78. doi: 10.1007/s00018-014-1584-5. Epub 2014 Feb 23. Cell Mol Life Sci. 2014. PMID: 24562347 Free PMC article. Review.
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Dal Bello MG, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, Rijavec E, Biello F, Bottoni G, Sambuceti G, Grossi F. Dal Bello MG, et al. Among authors: grossi f. Int J Cancer. 2015 Dec 15;137(12):2947-58. doi: 10.1002/ijc.29647. Epub 2015 Jul 15. Int J Cancer. 2015. PMID: 26089022
Vinflunine for the treatment of non-small cell lung cancer.
Genova C, Alama A, Coco S, Rijavec E, Dal Bello MG, Vanni I, Biello F, Barletta G, Rossi G, Grossi F. Genova C, et al. Among authors: grossi f. Expert Opin Investig Drugs. 2016 Dec;25(12):1447-1455. doi: 10.1080/13543784.2016.1252331. Epub 2016 Nov 1. Expert Opin Investig Drugs. 2016. PMID: 27771969 Review.
Advances in treatment of mesothelioma.
Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, Grossi F. Maggioni C, et al. Among authors: grossi f. Expert Opin Pharmacother. 2016 Jun;17(9):1197-205. doi: 10.1080/14656566.2016.1176145. Epub 2016 Apr 21. Expert Opin Pharmacother. 2016. PMID: 27055148 Review.
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.
Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Barni S, et al. Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19. Lung Cancer. 2015. PMID: 26314614 Free article.
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutilo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. Banna GL, et al. Among authors: grossi f. ESMO Open. 2021 Apr;6(2):100078. doi: 10.1016/j.esmoop.2021.100078. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33735802 Free PMC article.
528 results